Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV-MPL vaccine Formulation A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HBV-MPL vaccine Formulation A is a recombinant hepatitis B virus (HBV) vaccine formulated with 3-O-deacylated monophosphoryl lipid A (MPL) as an adjuvant. MPL is a detoxified derivative of lipopolysaccharide from *Salmonella enterica* and acts as a Toll-like receptor 4 (TLR4) agonist, stimulating dendritic cells and promoting Th1-type immune responses[6]. The formulation typically includes purified hepatitis B surface antigen (HBsAg), MPL, and may also contain aluminum phosphate as an additional adjuvant[5]. This combination enhances both humoral and cellular immunity against HBV, leading to strong antibody production and persistent CD4(+) T-cell responses[1][2]. The primary indication is prophylactic immunization against hepatitis B infection.
- Brand names
- Fendrix
- Other names
- HBV-MPL vaccine Formulation A
02
Targets
Hepatitis B surface antigen-recognizing B-cell and T-cell immune receptorsTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on HBV-MPL vaccine Formulation A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBV-MPL vaccine Formulation A.